Ingevity (NGVT) reported Q1 adjusted earnings late Monday of $0.99 per diluted share, up from $0.47 a year earlier.
Four analysts polled by FactSet expected $0.74.
Revenue for the quarter ended March 31 was $284 million, down from $340.1 million a year earlier.
Three analysts surveyed by FactSet expected $285.5 million.
Widening the bottom end of its guidance, the company now expects full-year 2025 sales of between $1.25 billion and $1.40 billion, compared with the $1.30 billion to $1.40 billion range set out in February. Analysts polled by FactSet expect $1.36 billion.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。